AdministrativeMedicaidNovember 21, 2023

Nirsevimab (Beyfortus™) available at no cost to prevent RSV in infants

The California Vaccines for Children (VFC) program will soon make Nirsevimab available at no cost to enrolled sites to prevent respiratory syncytial virus (RSV) infection in infants. California hospitals that serve infants eligible for VFC vaccines, including who are uninsured or covered by Medi-Cal Managed Care, are encouraged to enroll in the VFC program.

Nirsevimab is a long-acting monoclonal antibody that prevents severe disease from RSV, which causes as many as 80,000 hospitalizations and 300 deaths per year. In clinical trials, Nirsevimab has been highly effective in preventing hospitalization and intensive care admissions for RSV infection. In fact, Nirsevimab is now recommended after birth to all infants born between October and March, or later during infancy to those born in the spring or summer in the United States.

Nirsevimab has a list price of $495 per infant dose, so participation in the VFC program can save your hospital substantial costs. Select here to learn more about enrolling in the VFC program. You may also call the VFC program at 877-243-8832 for enrollment support.

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

CABC-CD-044858-23